ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit
- PMID: 14575996
- DOI: 10.1016/S0140-6736(03)14602-8
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit
Comment on
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x. Lancet. 2003. PMID: 12826431 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical